Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 17;22(22):12409.
doi: 10.3390/ijms222212409.

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents

Jelena Vekic  1 , Aleksandra Zeljkovic  1 , Aleksandra Stefanovic  1 , Rosaria Vincenza Giglio  2 , Marcello Ciaccio  2   3 , Manfredi Rizzo  4
Affiliations
Review

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents

Jelena Vekic et al. Int J Mol Sci. .

Abstract

Epidemiological data have demonstrated a significant association between the presence of type 2 diabetes mellitus (T2DM) and the development of colorectal cancer (CRC). Chronic hyperglycemia, insulin resistance, oxidative stress, and inflammation, the processes inherent to T2DM, also play active roles in the onset and progression of CRC. Recently, small dense low-density lipoprotein (LDL) particles, a typical characteristic of diabetic dyslipidemia, emerged as another possible underlying link between T2DM and CRC. Growing evidence suggests that antidiabetic medications may have beneficial effects in CRC prevention. According to findings from a limited number of preclinical and clinical studies, glucagon-like peptide-1 receptor agonists (GLP-1RAs) could be a promising strategy in reducing the incidence of CRC in patients with diabetes. However, available findings are inconclusive, and further studies are required. In this review, novel evidence on molecular mechanisms linking T2DM with CRC development, progression, and survival will be discussed. In addition, the potential role of GLP-1RAs therapies in CRC prevention will also be evaluated.

Keywords: glucagon-like peptide-1 receptor agonists; hyperglycemia; inflammation; insulin resistance; oxidative stress; small dense LDL.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest.

Figures

Figure 1
Figure 1
The role of insulin resistance in pathogenesis of CRC.
Figure 2
Figure 2
The role of hyperglycemia in pathogenesis of CRC (The figure was composed using Servier Medical Art templates, licensed under a Creative Common Attribution 3.0 https://smart.servier.com (accessed on 12 November 2021)).
Figure 3
Figure 3
Major sources of free radicals and main antioxidants.
Figure 4
Figure 4
Glucagon-like peptide-1 receptor agonist (GLP-1RAs) pleiotropic effects.
See this image and copyright information in PMC

References

    1. Tuomi T., Santoro N., Caprio S., Cai M., Weng J., Groop L. The many faces of diabetes: A disease with increasing heterogeneity. Lancet. 2014;383:1084–1094. doi: 10.1016/S0140-6736(13)62219-9. - DOI - PubMed
    1. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N., Colagiuri S., Guariguata L., Motala A.A., Ogurtsova K., et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. - DOI - PubMed
    1. Tsilidis K.K., Kasimis J.C., Lopez D.S., Ntzani E.E., Ioannidis J.P. Type 2 diabetes and cancer: Umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. doi: 10.1136/bmj.g7607. - DOI - PubMed
    1. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Pineros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019;144:1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. Ling S., Brown K., Miksza J.K., Howells L., Morrison A., Issa E., Yates T., Khunti K., Davies M.J., Zaccardi F. Association of Type 2 Diabetes with Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care. 2020;43:2313–2322. doi: 10.2337/dc20-0204. - DOI - PubMed

MeSH terms

Substances